API
< Back to situation

[REVISION HISTORY]

Fresenius Medical Care financial developments

1 recorded revision of this situation.

What changed

2026-11-11 11:27 UTC → 2026-11-13 10:51 UTC · added removed

Fresenius Medical Care (FMC) has engaged in several significant financial activities. The company issued a 500 million euro bond maturing in February 2032 with an annual coupon of 4.25 percent, intended for general corporate purposes and the refinancing of existing liabilities. The bond was issued at a price of 99.497 percent, resulting in an annual yield of 4.363 percent. Following third-quarter results, the company narrowed its 2026 operating profit outlook, now expecting results to range from a constant level to a mid-single-digit percentage decline. While revenue saw a 1 percent nominal increase to 4.937 billion euros, operating profit fell to 384 million euros from 477 million euros in the prior year. Net profit without special items also decreased to 160 million euros. The company cited operating performance and 108 million euros in special costs related to withdrawing from parts of its business in China as contributing factors factors. CEO Shervin Korangy stated that the company expects earnings development to fall within the revised guidance. lower half of the previously forecasted range. Additionally, Fresenius SE & Co. KGaA reduced its ownership stake in FMC from approximately 25 percent to about 20 percent by selling 13.4 million shares for approximately 524 million euros gross. The sale, completed at 39 euros per share, is intended to support growth investments as part of the “REJUVENATE phase.” Fresenius expects the gain to increase book profit by a low-to-mid double-digit amount in millions of euros, which will be classified as a special item in the final quarter of 2026.

Versions

  1. 2026-11-13 10:51 UTC Fresenius Medical Care financial developments
  2. 2026-11-11 11:27 UTC Fresenius Medical Care financial developments

Select a version to see what changed compared to the one before it.